Wedbush @Wedbush · 18 Aug 2026
Multiple sclerosis is complicated enough, especially when current treatments each add their own toxicity risks. Equity Research Analyst, Martin Fan, Ph.D. initiated coverage on @ImmunicInc (IMUX) at #OUTPERFORM with a $45 price target. Martin sees a de-risked readout for https://t.co/yLUMW0fdok
632Views
2Likes
0Reposts
1Replies
0Quotes
0Bookmarks
Is that a lot?
1.24×vs this author's median509 views is typical
60Percentile for this authorof 5 recent posts
0.20×vs 10K–100K median3 137 views is typical
5.37%Reachviews ÷ followers
0.47%Engagement rateof viewers reacted